Combined Immune Checkpoint Blockade

被引:12
|
作者
Drake, Charles G. [1 ,2 ,3 ,4 ]
机构
[1] James Buchanan Brady Urol Inst, Dept Oncol, Baltimore, MD USA
[2] James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
关键词
ACTIVATED T-CELLS; CANCER-IMMUNOTHERAPY; EFFECTOR FUNCTION; OVARIAN-CANCER; REGULATORY T; LAG-3; PD-1; IPILIMUMAB; AUTOIMMUNE; TIM-3;
D O I
10.1053/j.seminoncol.2015.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the majority of cancer patients. Immune checkpoint blockade can be combined with several other interventions, including radiation therapy, chemotherapy and cancer vaccines. However, the observation that T cells that are rendered not-responsive or "exhausted" by recognition of tumor antigens express multiple non-overlapping checkpoint molecules suggests that immunotherapy approaches in which multiple checkpoint molecules are blocked may be particularly active in the clinic. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 50 条
  • [41] Identification of resistance to immune checkpoint blockade
    Gu, Shengqing Stanley Gu
    Li, Ziyi
    Bu, Xia
    Xing, Xiaofang
    Freeman, Gordon
    Brown, Myles
    Liu, Xiaole Shirley
    [J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [42] Preclinical modelling of immune checkpoint blockade
    Stewart, Ross
    Mullins, Stefanie
    Watkins, Amanda
    Morrow, Michelle
    Sainson, Richard
    Robbins, Paul
    La Vallee, Theresa
    Wilkinson, Robert
    [J]. JOURNAL OF IMMUNOLOGY, 2013, 190
  • [43] The future of microfluidics in immune checkpoint blockade
    Jonathan Briones
    Wilfred Espulgar
    Shohei Koyama
    Hyota Takamatsu
    Eiichi Tamiya
    Masato Saito
    [J]. Cancer Gene Therapy, 2021, 28 : 895 - 910
  • [44] Immune checkpoint blockade in lymphoid malignancies
    Thanarajasingam, Gita
    Thanarajasingam, Uma
    Ansell, Stephen M.
    [J]. FEBS JOURNAL, 2016, 283 (12) : 2233 - 2244
  • [45] Fighting ageing with immune checkpoint blockade
    Crunkhorn, Sarah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (01) : 17 - 17
  • [46] Immune Checkpoint Blockade in Malignant Mesothelioma
    Calabro, Luana
    Maio, Michele
    [J]. SEMINARS IN ONCOLOGY, 2015, 42 (03) : 418 - 422
  • [47] Myocarditis with Immune Checkpoint Blockade REPLY
    Moslehi, Javid J.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 292 - 292
  • [48] Fertility post immune checkpoint blockade
    Ogle, Martinique
    Harrold, Emily
    O'Brien, Erin
    Weiss, Jill A.
    Yaqubie, Amin
    Sinopoli, Jenna Cohen
    Postow, Michael A.
    Cercek, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Sarcoidosis triggered by Immune Checkpoint Blockade
    Heppt, Markus
    Niesert, Anne-Charlotte
    Flaig, Michael
    Berking, Carola
    [J]. HAUTARZT, 2018, 69 : 11 - 13
  • [50] Renal complications of immune checkpoint blockade
    Murakami, Naoka
    Motwani, Shveta
    Riella, Leonardo V.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 100 - 110